scholarly journals An ultrasound risk-scoring model for prediction of endometrial cancer in post-menopausal women (using IETA terminology)

2017 ◽  
Vol 22 (3) ◽  
pp. 201-205 ◽  
Author(s):  
Nadia M. Madkour
Keyword(s):  
Endometrial Cancer ◽  
Scoring Model ◽  
Menopausal Women ◽  
Risk Scoring ◽  
Post Menopausal

Assessment of Risk Scoring Model for Prediction of Endometrial Cancer Among Symptomatic Postmenopausal Women (A Prospective Cohort Study)

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Magdy M Abd Elgawaad ◽  
Amr M El Helaly ◽  
Malames M Faisal ◽  
Asmaa F Kasem
Keyword(s):  
Endometrial Cancer ◽  
Family History ◽  
Endometrial Carcinoma ◽  
Endometrial Hyperplasia ◽  
Endometrial Thickness ◽  
Serous Carcinoma ◽  
Scoring Model ◽  
Gynecological Malignancy ◽  
Risk Scoring ◽  
Study Population

Abstract Background Endometrial carcinoma is the most common gynecological malignancy in the developed countries and the third common gynecological malignancy in Egypt after breast and ovarian cancers. Aim of the Work to evaluate this risk scoring model on Egyptian patients and to study the effect of adding other patient characteristics (DM, BMI and relevant family history) on the sensitivity and specificity of RHEA scoring model. Patients and Methods The current study was conducted in Ain Shams University Maternity Hospital in the period between September 2017 and December 2018. A total of 100 women with postmenopausal bleeding and endometrial thickness > 4mm were included in the study. Results Histological examination revealed that benign pathology (n = 65) (73%) was found to be: most common cause was endometrial hyperplasia without atypia (20.3%) followed by chronic endometritis (13.5%), then endometrial polyp (11.3%), cystic atrophy of endometrium (8.9%), proliferative endometrium (8.9%), endometrial hyperplasia with atypia (6.7%) and lastly mucous polyp (3.4%) while malignant histopathology(n = 24)(27%) which is significantly higher than the international rates showed: Endometriod adenocarcinoma (n = 19)(21.3%), papillary serous carcinoma (n = 4)(4.5%) and undifferentiated carcinoma (n = 1)(1.1%). The current study showed that RHEA score performs in our study population with a comparable validity to that reported by its inventors with sensitivity 79.2% (57.8% - 92.9%) vs. 87.5% and specificity 84.6% (73.5% - 92.4%) vs. 80.1% respectively. In results of the current study it was found that the time since onset of menopause rather than age was associated with endometrial cancer with the optimum cut-off for postmenopausal duration was estimated to be 9 years achieving a sensitivity of 87.5% and a specificity of 60.0%, but it needs multivariate analysis on larger and more representative sample size to confirm this association, A statistically significant regression model was including only postmenopausal duration, recurrent bleeding and endometrial thickness. None of age, BMI, family history or hypertension proved a statistically significant predictive effect after adjustment for other predictive variables. Conclusion Taking in consideration the higher prevalence of endometrial carcinoma in the sample of the current study, the wide 95% confidence intervals for the different validity indices for the RHEA scores derived from this study, it seems that RHEA score performs in this study population with a comparable validity to that reported by its inventors.

Tamoxifen and Endometrial Cancer

1996 ◽  
Vol 3 (2) ◽  
pp. 107-112 ◽  
Author(s):  
Richard R. Barakat
Keyword(s):  
Breast Cancer ◽  
Endometrial Cancer ◽  
Large Scale ◽  
Early Stage ◽  
Tamoxifen Treatment ◽  
Breast Cancer Patients ◽  
Menopausal Women ◽  
Overall Survival Benefit ◽  
Post Menopausal

Tamoxifen is commonly used in the management of patients with breast cancer. Clinical trials of tamoxifen involving over 75,000 patients demonstrate an improved recurrence-free and overall survival benefit in both pre- and post-menopausal women. Large-scale trials also are evaluating the role of tamoxifen as a chemopreventive agent in women considered to be at high risk for developing breast cancer based on family history. Endometrial cancer is an uncommon complication of tamoxifen therapy. Since the majority of these cancers will be detected at an early stage when they are highly curable, however, the overall benefit of tamoxifen treatment in breast cancer patients outweighs this risk. All women receiving tamoxifen who have a uterus should undergo regular gynecologic examinations.

Fertility-preserving Management of Endometrial Carcinoma

2011 ◽  
Vol 07 (03) ◽  
pp. 191
Author(s):  
Luis M Chiva ◽  
Sonsoles Alonso ◽  
◽  
Keyword(s):  
Endometrial Cancer ◽  
Hormonal Treatment ◽  
Disease Stage ◽  
Low Grade ◽  
Reproductive Outcome ◽  
Early Disease ◽  
Gynaecological Malignancy ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Early Disease Stage

Endometrial cancer is the most common gynaecological malignancy, usually diagnosed in post-menopausal women. However, an incidence of 2–14 % of cases occurring in women <45 years of age has been reported. In this group of younger patients, because of the childbearing challenges, there is an increased percentage of nulliparity. Due to the early disease stage and the low grade of differentiation at the time of diagnosis, an improved prognosis has been reported in this group of patients. Many reports have described conservative treatment of this tumour in selected patients with the aim of preserving fertility. In this article, we review the literature for a better assessment of selection criteria, risk of concomitant neoplasias, hormonal treatment and clinical and reproductive outcome. We have concluded that fertility-preserving management of endometrial cancer is feasible in selected patients with an acceptable clinical and reproductive outcome.

scholarly journals A Risk-Scoring Model for the Prediction of Endometrial Cancer among Symptomatic Postmenopausal Women with Endometrial Thickness > 4 mm

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Luca Giannella ◽  
Kabala Mfuta ◽  
Tiziano Setti ◽  
Lillo Bruno Cerami ◽  
Ezio Bergamini ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Postmenopausal Women ◽  
Vaginal Bleeding ◽  
Risk Model ◽  
Endometrial Thickness ◽  
Patient Characteristics ◽  
Roc Curve Analysis ◽  
Decision Algorithm ◽  
Scoring Model ◽  
Risk Scoring

Objective. To develop and test a risk-scoring model for the prediction of endometrial cancer among symptomatic postmenopausal women at risk of intrauterine malignancy.Methods. We prospectively studied 624 postmenopausal women with vaginal bleeding and endometrial thickness > 4 mm undergoing diagnostic hysteroscopy. Patient characteristics and endometrial assessment of women with or without endometrial cancer were compared. Then, a risk-scoring model, including the best predictors of endometrial cancer, was tested. Univariate, multivariate, and ROC curve analysis were performed. Finally, a split-sampling internal validation was also performed.Results. The best predictors of endometrial cancer were recurrent vaginal bleeding (odds ratio(OR)=2.96), the presence of hypertension(OR=2.01)endometrial thickness > 8 mm(OR=1.31), and age > 65 years(OR=1.11). These variables were used to create a risk-scoring model (RHEA risk-model) for the prediction of intrauterine malignancy, with an area under the curve of 0.878 (95% CI 0.842 to 0.908;P<0.0001). At the best cut-off value (score ≥ 4), sensitivity and specificity were 87.5% and 80.1%, respectively.Conclusion. Among symptomatic postmenopausal women with endometrial thickness > 4 mm, a risk-scoring model including patient characteristics and endometrial thickness showed a moderate diagnostic accuracy in discriminating women with or without endometrial cancer. Based on this model, a decision algorithm was developed for the management of such a population.

scholarly journals Adjuvant treatment of endometrial cancer today

2020 ◽  
Vol 50 (7) ◽  
pp. 753-765
Author(s):  
Yoichi Aoki ◽  
Hiroyuki Kanao ◽  
Xipeng Wang ◽  
Mayu Yunokawa ◽  
Kohei Omatsu ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Endometrial Cancer ◽  
Adjuvant Therapy ◽  
Advanced Disease ◽  
Early Stage ◽  
Cancer Stage ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Histopathological Results

Abstract Endometrial cancer frequently occurs in post-menopausal women, and the endometrium is a well-known site of cancer affecting women. Endometrial cancer is found with genital bleeding and often at an early stage. However, there are some risks of recurrence after hysterectomy. As a medical treatment after the diagnosis of endometrial cancer, appropriate adjuvant therapy is considered to lead to a decrease in the rate of recurrence and improvement of prognosis according to the determination of the cancer stage from the surgical and histopathological results. In this review, we describe post-operative adjuvant therapy administered for endometrial cancer and advanced disease, focusing on chemotherapy, radiation therapy and the combination of both. These treatments are divided according to the risk of recurrence as based primarily on the reported evidence.

scholarly journals The Combinatory Effects of Glabridin and Tamoxifen on Ishikawa and MCF-7 Cell Lines

2015 ◽  
Vol 10 (9) ◽  
pp. 1934578X1501000 ◽  
Author(s):  
Soe Hui Jen ◽  
Melissa Poh Su Wei ◽  
Adeline Chia Yoke Yin
Keyword(s):  
Endometrial Cancer ◽  
Replacement Therapy ◽  
Cell Lines ◽  
Estrogen Replacement Therapy ◽  
Estrogen Receptor Α ◽  
Estrogen Replacement ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Mtt Assays ◽  
Mcf 7

Estrogen replacement therapy is commonly used to replace the loss of estrogen in post-menopausal women. However, it is not suitable to be used in women taking tamoxifen as both of the drugs increase the risk of endometrial cancer. This project aimed to study the potential of using the natural compound glabridin in combination with tamoxifen as a drug for estrogen replacement therapy. Ishikawa and MCF-7 cells were used to investigate the estrogenic activities stimulated by the combination of tamoxifen and glabridin through ALP and MTT assays. The expressions of the ESR1 and bcl-2 genes have also been determined using RT-PCR. The results indicated that the combination of 1×10−5M tamoxifen and 1×10−6M glabridin exhibited estrogenic activities and suppressed cell growth in both cell lines. The relative expressions of ESR1 and bcl-2 genes indicated that the estrogenicity expressed by the combinatory drug was regulated by estrogen receptor α; however, the reduction in cell proliferation was not modulated by bcl-2 anti-apoptotic proteins. These results suggested that the combination of tamoxifen and glabridin has potential to be used as an estrogen replacement drug with a reduced risk of endometrial cancer that has arisen from the intake of tamoxifen.

Sign in / Sign up

Export Citation Format

Share Document